Retrospective large database studies have shown that L-DOPA exposure is associated with delayed age of onset of both AMD and neovascular AMD, decreased intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection burden, and reduced conversion to neovascular AMD [13–15]. The gene discussed is VEGFA; the disease is age-related macular degeneration.